The role of ApoE has been well-studied outside of the cell, but what happens after it’s let inside? Scientists led by Raimund Dutzler, University of Zurich, have identified Tweety homologue 2 as an ...

p-Tau217 might be the Benjamin Button of biomarkers—starting off old and ending up young. Seriously, p-tau217 is unusually high at birth before waning with age, scientists report. In a cross-sectional ...

Two studies analyzed tau-PET scans from thousands of participants in dozens of cohorts. Tangle prevalence increased with age among cognitively normal people, but decreased among those with dementia.

Every participant in the Dutch 100-Plus study is, by definition, exceptional. Just to qualify for enrollment, they must have remained cognitively healthy even after logging 100 laps around the sun.

Postdoctoral Position- Neurobiology of Parkinson’s Disease JOB 2025-07-09 Employer Université Laval Contact aurelie.jacquet@crchudequebec.ulaval.ca Description The team specializes in the study of ...

This widely used tauopathy model was developed at the University of Pennsylvania School of Medicine by Virginia Lee, John Trojanowski, and colleagues. As first reported in 2007 on a mixed background, ...

Lina Schmidt, Dr.Contact Information Lina Schmidt, Dr.

Research News Parkinsonian disorders are difficult to diagnose. Clinical symptoms often overlap ...

Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional) (RFA-FD-25-017) Grants Home ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

In a Phase 2 trial, donanemab completely cleared plaque in two-thirds of participants. Their cognitive decline slowed by a third, meeting the primary endpoint. The treatment appeared to nudge down ...